Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Choreo LLC

Choreo LLC grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 53.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 8,147 shares of the biopharmaceutical company’s stock after purchasing an additional 2,844 shares during the period. Choreo LLC’s holdings in Gilead Sciences were worth $660,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in GILD. Clearbridge Investments LLC increased its position in Gilead Sciences by 179.0% during the 3rd quarter. Clearbridge Investments LLC now owns 4,543,985 shares of the biopharmaceutical company’s stock worth $340,526,000 after purchasing an additional 2,915,141 shares during the period. abrdn plc increased its position in Gilead Sciences by 89.0% during the 4th quarter. abrdn plc now owns 3,764,107 shares of the biopharmaceutical company’s stock worth $304,930,000 after purchasing an additional 1,772,887 shares during the period. International Assets Investment Management LLC acquired a new position in Gilead Sciences during the 4th quarter worth approximately $133,584,000. AEGON ASSET MANAGEMENT UK Plc purchased a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $63,971,000. Finally, Bailard Inc. boosted its stake in shares of Gilead Sciences by 9,100.7% during the 3rd quarter. Bailard Inc. now owns 722,345 shares of the biopharmaceutical company’s stock worth $54,133,000 after acquiring an additional 714,494 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the sale, the insider now directly owns 96,304 shares in the company, valued at approximately $7,026,339.84. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on GILD shares. TD Cowen reduced their target price on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Friday, April 26th. Truist Financial lowered Gilead Sciences from a “buy” rating to a “hold” rating and reduced their target price for the company from $91.00 to $82.00 in a research note on Thursday, February 22nd. StockNews.com raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 27th. Mizuho reduced their target price on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a research note on Thursday, February 22nd. Finally, Maxim Group reduced their target price on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Wednesday. Eleven investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $83.69.

Gilead Sciences Trading Up 0.5 %

GILD stock opened at $65.51 on Thursday. The company has a market cap of $81.57 billion, a price-to-earnings ratio of 181.97, a PEG ratio of 1.31 and a beta of 0.22. The company has a quick ratio of 0.72, a current ratio of 0.98 and a debt-to-equity ratio of 1.08. The business has a fifty day simple moving average of $70.87 and a 200-day simple moving average of $76.01. Gilead Sciences, Inc. has a 52 week low of $64.63 and a 52 week high of $87.86.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. The business had revenue of $6.69 billion during the quarter, compared to the consensus estimate of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the prior year, the firm posted $1.37 EPS. On average, equities research analysts expect that Gilead Sciences, Inc. will post 3.74 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be issued a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.70%. Gilead Sciences’s payout ratio is 855.56%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.